[go: up one dir, main page]

WO2018164369A1 - Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif - Google Patents

Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif Download PDF

Info

Publication number
WO2018164369A1
WO2018164369A1 PCT/KR2018/000594 KR2018000594W WO2018164369A1 WO 2018164369 A1 WO2018164369 A1 WO 2018164369A1 KR 2018000594 W KR2018000594 W KR 2018000594W WO 2018164369 A1 WO2018164369 A1 WO 2018164369A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
enzyme
treated
skin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/000594
Other languages
English (en)
Korean (ko)
Inventor
이태후
양정은
황은선
박상용
김슬아
박설웅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sd Biotechnologies Co Ltd
Original Assignee
Sd Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sd Biotechnologies Co Ltd filed Critical Sd Biotechnologies Co Ltd
Priority to CN201880001049.5A priority Critical patent/CN108834400B/zh
Publication of WO2018164369A1 publication Critical patent/WO2018164369A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5775—Hibiscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95

Definitions

  • the present invention relates to a composition for improving skin wrinkles, and more particularly to a composition for improving skin wrinkles containing an enzyme-treated rose of sharon as an active ingredient.
  • Skin wrinkles are known to be affected by various factors such as skin moisture content, collagen content, and immunity to the external environment.
  • the most important factors affecting the formation of double wrinkles are collagen production and collagenase, a collagen degrading enzyme. Naze expression and activity.
  • Collagen is present in the dermal layer of the skin and is known as a major ingredient that gives skin elasticity with elastin, which accounts for about 70-80% of the total dry weight of the skin. Collagen is reduced by internal factors such as decreased cellular activity due to natural aging, and biosynthesis is reduced or degradation is accelerated by external factors such as increased stress in various harmful environments or increased free radical species by sunlight. have.
  • ROS reactive oxygen species
  • MAPKs mitogen activated protein kinases
  • ERK extracellular signal-regulated kinase
  • JNK c-Jun amino-terminal kinase
  • AP-1 protein is associated with the activity of matrix metalloproteinase (MMP) gene
  • MMP matrix metalloproteinase
  • Type I collagen is the most abundant protein in the extracellular matrix of connective tissue. Extracellular matrix includes other types of proteins such as type III, V, and VII collagen, elastin, proteoglycans, fibronectin.
  • Controlling the expression level of type I collagen protein is the most important factor in preventing skin photoaging. Irradiation of UVB reduces expression of collagen precursor procollagen in skin fibroblasts through inhibition of the TGF- ⁇ / Smad signaling system. In addition, the TGF- ⁇ 1 signaling system is one of the important factors regulating the synthesis of extracellular matrix in human skin fibroblasts.
  • ROS reactive oxygen species
  • Mugunghwa Hugunghwa; Hibiscus syriacus L.
  • the national flower of Korea is known to have about 200 species in Korea alone. It has been used as a medicinal plant having the efficacy of.
  • Mugunghwa is the national flower of Korea, only the research on the cultivation and breeding of Mugunghwa has been mainly conducted in Korea until now, and various studies of physiological activity using Mugunghwa are insufficient, and in particular, functional cosmetics or foods applicable to life Very few studies have been developed as raw materials.
  • bioconversion technology has the advantage of increasing the functionality of natural products and securing a large amount of potent substances.
  • composition for improving pruritus with herbal extracts' includes Chihwang, Seokchangpo, Yellow and White, Red Ginseng, bamboo Leaf, Licorice, Prunus, Mokeunpi, Kwandonghwa, Janggunpi and Neck and Extract It is disclosed that the composition for improving pruritus containing as an anti-inflammatory effect, moisture moisturizing effect and wrinkle improvement effect, but the effect is the same as the above only by combining the 11 herbal ingredients, the single composition The effect of improving skin wrinkles is not mentioned at all.
  • Mugunghwa as an ingredient of the cosmetic composition, which can be used safely because it is harmless to the human body and easily obtains raw materials, it is used in combination with other plant materials such as Patent Application No. 10-2011-0125087. There was a problem that should be.
  • the present inventors have intensively researched to maximize the skin wrinkle improvement effect of Rose of Sharon and utilize it as a main ingredient of the cosmetic composition, and as a result, human fibroblasts induced by UVB irradiation when the Rose of Rose extract was treated with glycolytic enzymes (human In response to photoaging of dermal fibroblasts (NHDFs), it has been found to have an excellent effect on anti-oxidation, anti-inflammatory and skin wrinkle improvement, thus completing the present invention.
  • human fibroblasts induced by UVB irradiation when the Rose of Rose extract was treated with glycolytic enzymes human In response to photoaging of dermal fibroblasts (NHDFs)
  • the present invention provides a cosmetic composition for improving skin wrinkles comprising a glycolytic enzyme-treated rose of sharon as an active ingredient.
  • extract refers to an extract obtained by extracting a plant, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, a mixture thereof, or the like, It includes the extract itself and extracts of all formulations that can be formed using the extract.
  • the extract of the present invention may be preferably prepared and used in the form of a dry powder after extraction.
  • the Rose of Sharon extract can be extracted from the natural, hybrid or cultivated plants of Rose of Sharon, can be extracted from plant tissue culture, preferably from the bark of the stem and root have.
  • the method for preparing the extract may be a conventional extraction method in the art, such as ultrasonic extraction, leaching and reflux extraction.
  • Solvents used for extraction are water, alcohols or mixtures thereof, preferably methanol or ethanol, but are not limited to these.
  • the amount of the extraction solvent may be used 2 to 50 times by weight of the sample, preferably 2 to 20 times.
  • the sample may be left for 1 to 72 hours for leaching in the extraction solvent, preferably for 24 to 48 hours.
  • glycolytic enzyme of the present invention means an enzyme that catalyzes the reaction, and in the present invention, it means an enzyme that decomposes carbohydrates such as cellulose, amylose, tannin, and pectin.
  • examples of the glycolysis enzymes include cellulase, hemicellulase, pectinase, glucosidase, tanase, but not limited thereto. If the enzyme has the activity of breaking down the polysaccharide form of the polymer present in the green light extract is included in the glycolysis enzyme of the present invention.
  • the glycolysis enzyme is one or more enzymes selected from the group consisting of hemicellulase, pectinase, glucosidase, and tanase desirable.
  • the enzymes may be used alone or in combination with these enzymes.
  • the glycolytic enzyme is preferably an enzyme mixed with pectinase and hemicellulase, wherein the preferred mixing ratio is pectinase to hemicellulase 1: 1 to 1: 5 or Pectinase to hemicellulase 1: 1 to 5: 1 is preferred. If the mixing ratio is not satisfied, the content of the active ingredient in the glycolysis-treated rose of Sharon extract is relatively reduced.
  • improve skin wrinkles means skin regeneration, skin elasticity improvement, skin wrinkle prevention or improvement, or skin inflammation improvement.
  • skin aging refers to all diseases caused by an increase in reactive free radicals, and non-limiting examples of the skin aging include wrinkles, sagging of the skin, decrease in elasticity and the like.
  • composition for improving skin condition of the present invention protects DNA, proteins (including lipoproteins) and membrane lipids from oxidative damage with an excellent free radical removal effect.
  • skin regeneration or “improve skin elasticity” or “prevent or improve skin wrinkles” refers to any action that increases the production of collagen or inhibits the breakdown of collagen to increase the total amount of collagen.
  • skin wrinkle refers to the lines produced by the skin decay, can be caused by the cause of genes, the reduction of collagen present in the dermis of the skin, the external environment.
  • preventing or improving skin wrinkles refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating wrinkles already generated.
  • the main functions of skin fibroblasts include the regeneration of damaged skin tissue through extracellular matrix synthesis and proliferation.
  • Extracellular matrix synthesis factors such as photoaging or accumulation of damage caused by free oxygen and cellular aging due to telomeres breakdown They lower the physiological activity of dermal fibroblasts in the dermis.
  • Type I collagen which accounts for more than 95% of the extracellular matrix of the skin, plays a very important part in the physiological activity of fibroblasts through interactions and signal exchanges with cell adhesion molecules and cytoskeleton.
  • the synthesis of is decreased, the amount of collagen in the skin tissue is reduced, thereby reducing the surface tension to reduce the skin elasticity and wrinkles of the skin, as well as reducing the bioactive function, including the proliferation and regeneration of the cells cause a vicious cycle.
  • collagen of dermal fibroblasts can be seen to be directly related to the repair or regeneration of tissue during skin regeneration, skin elasticity, skin wrinkle formation and skin damage.
  • 'MMP' matrix metallo-proteinase
  • composition comprising the glycolysis-treated Mugunghwa extract of the present invention as an active ingredient is characterized by increasing the expression of type I procollagen protein and inhibiting the expression of MMP-1 protein and MMP-3 protein.
  • the composition comprising the enzyme-treated Mugunghwa extract of the present invention reduces the expression of MMP-1 and MMP-3 to reduce cytotoxicity and promote collagen degradation in normal human dermal fibroblasts (NHDF) irradiated with ultraviolet light.
  • NHDF normal human dermal fibroblasts
  • improvement means any action that at least reduces the parameters associated with alleviation or treatment of a condition, such as the degree of symptoms.
  • Enzyme-treated rose of sharon extract contained in the cosmetic composition for improving skin wrinkles of the present invention is effective in improving skin wrinkles by itself, even when used in combination with materials known to be effective in improving skin wrinkles.
  • the effect of improving skin wrinkles can be sustained.
  • the material that is effective in improving the skin wrinkles is not limited to this, chamomile flower extract, rosemary leaf extract, pasqueflower leaf extract, Ersnier extract, ginseng extract, geranium flower extract, ginseng extract, St. Mary's extract, thyme extract, Nettle extract, yarrow extract, clove extract, fennel extract, papaya leaf extract, sunflower extract, eucalyptus extract, and angelica extract.
  • the cosmetic composition of the present invention may further include a water-soluble vitamin, a fat-soluble vitamin, a polymer peptide, a polymer polysaccharide, a sphingolipid and a seaweed extract.
  • the water-soluble vitamins may be any one that can be formulated in cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H And salts thereof (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) may also be used in the present invention. Included in water-soluble vitamins.
  • the water-soluble vitamin can be obtained by a conventional method such as microbial conversion, microbial culture purification, enzyme method or chemical synthesis.
  • the fat-soluble vitamins may be any one that can be formulated in cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E, and the like, and derivatives thereof (ascorbic palmitate, ascorbic acid stearate). Bin, dipalmitinate, ascorbate, dl-alpha tocopherol acetate, dl-alpha tocopherol vitamin E, DL-pantothenyl alcohol, D-pantotenyl alcohol, pantothenyl ether, etc.) do.
  • the polymer peptide may be any compound that can be formulated in cosmetics, and preferably collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin and the like.
  • the polymer peptide can be purified and obtained by a conventional method such as purification method of microbial culture solution, enzyme method or chemical synthesis method, or can be purified and used from natural products such as dermis such as pig or cow and silk fiber of silkworm.
  • the polymer polysaccharide may be any compound as long as it can be blended into cosmetics.
  • hydroxyethyl cellulose, xanthan gum, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be mentioned.
  • chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.
  • the sphingolipide may be any compound as long as it can be blended into cosmetics, and preferably, ceramide, phytosphingosine, sphingose sugar lipid, and the like.
  • the sphingolipids can usually be purified from mammals, fish, shellfish, yeasts or plants by conventional methods or obtained by chemical synthesis.
  • the seaweed extract may be any one that can be formulated in cosmetics, but may preferably include brown algae extract, red algae extract, green algae extract, and the like, and calginane, arginic acid, and arginic acid purified from these seaweed extracts.
  • Sodium, potassium arginate and the like are also included in the seaweed extract used in the present invention.
  • Seaweed extract can be obtained by purification from seaweed by conventional methods.
  • the cosmetic of the present invention may be blended with the above essential components, if necessary, with other ingredients normally blended into the cosmetic.
  • blending component examples include oil or fat components, humectants, emollients, ultraviolet absorbers, pH adjusters, flavoring agents, blood circulation accelerators, cooling agents, limiting agents, purified water and the like.
  • fat or oil components examples include ester fats, hydrocarbon fats, silicone fats, fluorine fats, animal fats, and vegetable fats and oils.
  • ester fats and oils examples include glyceryl tri2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl mystinate, isopropyl palmitate, ethyl stearate, octyl palmitate, and isocetyl isostearate, Butyl stearate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocyanate isocetyl, isostearyl mysterylate, isostearyl palmitate, octylate acid octyldodecyl, isocetyl isostearate, diethyl sebacate, Diisopropyl adipropyl, isoalkyl neopentane, tri (capryl, capric acid) glyceryl, trimethyl ethyl trimethylo
  • hydrocarbon-based oils and fats examples include hydrocarbon-based oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, and vaseline.
  • the silicone-based fats and oils include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane methylcetyloxysiloxane copolymer, dimethylsiloxane methylsteoxysiloxane copolymer, and alkyl.
  • Modified silicone oil amino modified silicone oil and the like.
  • Perfluoro polyether etc. are mentioned as said fluorine-based fats and oils.
  • the animal or plant oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, corn oil, rapeseed oil, almond oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil, cottonseed oil, palm oil, Cucumber nut oil, wheat germ oil, rice germ oil, shea butter, moon sour colostrum, marker demia nut oil, egg yolk oil, tallow, horse oil, mink oil, orange rape oil, jojoba oil, canderry wax, carnauba wax, liquid ranol And animal or plant fats and oils such as hardened castor oil.
  • the moisturizing agent examples include a water-soluble low molecular moisturizer, a fat-soluble molecular moisturizer, a water-soluble polymer, and a fat-soluble polymer.
  • fat-soluble low molecular humectants examples include cholesterol and cholesterol esters.
  • water-soluble polymer examples include carboxyvinyl polymer, polyasparaginate, tragacanth, xanthan gum, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, water soluble chitin, chitosan, and dextrin. Can be mentioned.
  • the fat-soluble polymer examples include polyvinylpyrrolidone eicosene copolymer, polyvinylpyrrolidone hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, polymer silicone, and the like.
  • emollient examples include long-chain acyl glutamic acid cholesteryl ester, hydroxy stearic acid cholesterol, 12-hydroxystearic acid, stearic acid, rosin acid, lanolin fatty acid cholesteryl ester, and the like.
  • Examples of the ultraviolet absorber include paraaminobenzoic acid, ethyl paraaminobenzoate, amyl paraaminobenzoic acid, octyl paraaminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, Cinnamic acid benzyl, paramethoxy cinnamic acid-2-ethoxyethyl, paramethoxy cinnamic acid octyl, diparamethoxy cinnamic acid mono-2-ethylhexane glyceryl, paramethoxy cinnamic acid isopropyl, diisopropyl diisopropyl cinnamic acid ester mixture , Urocanoic acid, ethyl urocanate, hydroxymethoxybenzophenone,
  • pH adjuster examples include citric acid, sodium citrate, malic acid, sodium malate, fmaric acid, sodium fmarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, and the like.
  • Cosmetics prepared by containing the composition of the present invention may take the form of solutions, emulsions, viscous mixtures and the like.
  • the components included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the components as an active ingredient, for example, conventional auxiliaries such as stabilizers, pigments and natural flavors and It may further include a carrier.
  • composition of the present invention can be used in various ways, such as cosmetics or face wash having the effect of improving skin wrinkles.
  • composition of the present invention can be added, for example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream
  • Cosmetics such as foundations, essences, nutritional essences, packs and the like, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions, feminine cleansers, hand cleansers, and body cleansers.
  • the formulation of the present invention is a paste, cream or gel
  • animal carriers vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc.
  • carrier components can be used as carrier components.
  • lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellants such as butane or dimethyl ether.
  • a solvent, solvating agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • the present invention provides a pharmaceutical composition for improving skin wrinkles comprising a glycolytic enzyme-treated rose of sharon as an active ingredient.
  • the glycolytic enzyme is preferably an enzyme mixed with pectinase and hemicellulase, wherein the preferred mixing ratio is pectinase to hemicellulase 1: 1 to 1: 5 or Pectinase to hemicellulase 1: 1 to 5: 1 is preferred. If the mixing ratio is not satisfied, the content of the active ingredient in the glycolysis-treated rose of Sharon extract is relatively reduced.
  • the glycolysis-treated Mugunghwa extract increases the expression of type I procollagen protein and inhibits the expression of MMP-1 and MMP-3 proteins. do.
  • composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • compositions of the invention may also be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds.
  • Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • composition of the present invention diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • composition of the present invention is administered directly to the skin in the form of an external preparation for application to the skin in the form of an external preparation for creams, gels, patches, sprays, ointments, warnings, lotions, linens, pastas or cataplasmas. It may be, but is not limited thereto.
  • Preferred dosages of the mixed compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration of administration, and may be appropriately selected by those skilled in the art, preferably 0.01 ⁇ g / ml to 25 It may be administered at a dose of ⁇ g / ml. Topical administration may be administered once a day or may be divided several times.
  • the cosmetic and pharmaceutical compositions of the present invention can be directly used as a composition for improving skin wrinkles because they have an effect on skin wrinkle improvement, antioxidant and anti-inflammatory, and contain other natural extracts effective for skin wrinkle improvement. It is also available in the form of mixing with the ingredients, it is expected to enhance the skin wrinkle improvement effect of the existing materials.
  • the composition comprising the glycolytic enzyme-treated Mugunghwa extract of the present invention as an active ingredient inhibits the expression of MMP-1 and MMP-3 in human dermal fibroblasts and increases the production of type I procollagen, It is effective in preventing the occurrence of skin wrinkles and improving wrinkles of damaged skin.
  • composition of the present invention is excellent in the efficacy of preventing, ameliorating or treating skin aging and skin inflammation.
  • composition of the present invention is a substance derived from natural products, it is not toxic, and does not cause side effects even when applied to the human body, and thus has high utility as a cosmetic, quasi-drug, food or pharmaceutical composition.
  • Figure 1 is a graph showing the effect of glycolysis-treated green light extract and unenzymatic green light extract on cell survival.
  • Figure 2 is a graph comparing the results of Chromatography analysis of the glycolysis-treated green light extract and unenzymatic green light extract.
  • Figure 3 is a graph comparing the radical scavenging activity effect (DPPH assay) of the glycolysis-treated green light extract and unenzymatic green light extract.
  • Figure 4 is a graph comparing the anti-inflammatory activity of the glycolysis-treated green light extract and unenzymatic green light extract.
  • FIG. 5 is a graph comparing the effects of glycolysis-treated Mugunghwa extract and unenzymatic Mugunghwa extract on MMP-1 protein expression in UVB-irradiated human fibroblasts.
  • FIG. 6 is a graph comparing the effects of glycolysis-treated Mugunghwa extract and unenzymatic Mugunghwa extract on the expression of type I procollagen protein in UVB-irradiated human fibroblasts.
  • FIG. 7 is a graph comparing the radical scavenging activity effect (ABTS assay) between the glycolytic enzyme-treated rose of sharon of Example 1 and the rose of sharon, which was treated with the other enzymes of Comparative Examples 2 and 3.
  • FIG. 7 is a graph comparing the radical scavenging activity effect (ABTS assay) between the glycolytic enzyme-treated rose of sharon of Example 1 and the rose of sharon, which was treated with the other enzymes of Comparative Examples 2 and 3.
  • FIG. 8 is a graph comparing the effects of the glycolysis-treated Mugunghwa extract of Example 1 and the Mugunghwa extract treated with other enzymes of Comparative Examples 2 and 3 on the expression of MMP-1 protein in UVB-irradiated human fibroblasts.
  • the enzyme-added solution was placed in a constant temperature water bath and stirred at 60 ° C. for 24 hours to react with the enzyme. After the completion of the reaction, 14% by weight of 100% ethanol was added again, the mixture was extracted with stirring overnight, and the supernatant was lyophilized to be used as an example.
  • the green light extract was prepared in the same manner except that the process of Example 1 was not carried out using an enzyme.
  • the green light extract was prepared in the same manner as in Example 1, except that glucoamylase was used instead of pectinase and hemicellulase mixed in a 1: 1 weight ratio as an enzyme.
  • the green light extract was prepared in the same manner as in Example 1 except that lactase was used instead of pectinase and hemicellulase mixed in a 1: 1 weight ratio as an enzyme.
  • Extract components prepared in Example 1 and Comparative Example 1 were analyzed using the chromatography equipment according to the conditions of Table 1 below.
  • the glycolysis-treated green light extract was 271% at 1, 10, 50, 100, and 250 ⁇ g / ml doses compared to the non-enzymatic green light extract, respectively. It was observed that the antioxidant activity was improved by 136%, 308%, 422%, and 249%, and the levels of these antioxidant effects were observed to be almost equivalent to the positive control arbutin.
  • Enzyme-treated rose of sharon 1 was prepared at concentrations of 1, 10, 50, 100, and 250 ⁇ g / mL, respectively, and dispensed into 96-well plates, mixed with ABTS solution to block light, and reacted for 37 to 10 minutes. The absorbance was then measured at 734 nm using a microplate reader (Molecular Devices FilterMax F5; San Francisco, CA, USA). At this time, the well-known antioxidant arbutin was treated at the same concentration and used as a positive control group, and the antioxidant capacity of the sample was obtained by calculating the absorbance of the no addition group and expressed as a percentage as follows.
  • the green light extract treated with the glycolysis enzyme used in the present invention has a superior radical scavenging activity and almost the same effect as arbutin compared to the green light extract treated with glucoamylase or lactase .
  • DMEM 2 ml of DMEM was added to a 40 mm cell culture dish, and human fibroblasts were seeded at a concentration of about 1.2 ⁇ 10 5 , followed by incubation for 24 hours at 37 ° C. and 5% CO 2 . Thereafter, UVB was irradiated under 144 mJ / cm 2 condition, and then cultured for 3 days by replacing with a medium containing glycolytic enzyme-treated rose of sharon (10, and 100 ⁇ g / ml, respectively) prepared in Example 1. The culture was then harvested and centrifuged at 4 ° C. and 7500 rpm for 5 minutes using MISA-1 and MMP-3 (Human Total MMP-1 kit, R & D Systems, Inc., Minneapolis, MN, USA) changes in protein expression levels were confirmed.
  • MISA-1 and MMP-3 Human Total MMP-1 kit, R & D Systems, Inc., Minneapolis, MN, USA
  • the glycolysis-treated Mugunghwa extract of the present invention can be effectively used for the prevention and improvement of skin wrinkles by effectively inhibiting the expression of MMP-1 and MMP-3 proteins that cause wrinkles could know.
  • Comparative Example 2 and Comparative Example treated with lactase treated with Glycolytic enzyme-treated Mugunghwa extract of Example 1 and glucoamylase in human fibroblasts irradiated with UVB to compare and confirm the activity of the glycolysis enzyme used in the present invention The effect of Mugunghwa extract of 3 on the expression of MMP-1 protein is shown in FIG. From the contents of FIG. 8, it was confirmed that the green light extract treated with the glycolysis enzyme used in the present invention more effectively inhibits the expression of MMP-1 protein than the green light extract treated with glucoamylase or lactase.
  • Human fibroblasts treated with UV radiation at a dose of 144 mJ / cm 2 had a 2.1-fold reduction in the production of type 1 procollagen protein compared to the UV-treated group.
  • the decrease in production of type 1 procollagen protein due to UV irradiation showed a phenomenon of increasing again by the treatment of Mugunghwa extract.
  • the glycolysis-treated Mugunghwa extract treatment group showed a superior increase effect compared to the non-enzyme-treated group, which produced 130% and 177% of type 1 procollagen protein at 10, and 100 ⁇ g / ml doses, respectively.
  • the increase effect was shown (FIG. 6).
  • the composition for improving skin wrinkles comprising the glycolysis-treated Mugunghwa extract of the present invention has an antioxidant effect equivalent to that of arbutin, and acts on TGF- ⁇ / Smad signaling system of type 1 procollagen.
  • TGF- ⁇ / Smad signaling system of type 1 procollagen acts on TGF- ⁇ / Smad signaling system of type 1 procollagen.
  • the composition of the present invention is excellent in preventing, ameliorating or treating skin aging and skin inflammation, and is non-toxic because it is a substance derived from natural products, and does not cause side effects even when applied to the human body, cosmetics, quasi-drugs, food or pharmaceutical compositions. High utilization of furnace.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour améliorer les rides de la peau, contenant un extrait d'Hibiscus syriacus traité par une enzyme glycolytique en tant que principe actif. La composition de la présente invention inhibe l'expression de la protéine MMP-1 dans les fibroblastes dermiques humains et augmente la production de procollagène de type I, ce qui permet de prévenir l'apparition des rides dans la peau et d'améliorer les rides d'une peau endommagée. Globalement, la composition de la présente invention peut prévenir et améliorer considérablement les rides de la peau.
PCT/KR2018/000594 2017-03-07 2018-01-12 Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif Ceased WO2018164369A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880001049.5A CN108834400B (zh) 2017-03-07 2018-01-12 含有酶处理的木槿提取物作为有效成分的用于改善皮肤皱纹的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0028629 2017-03-07
KR20170028629 2017-03-07

Publications (1)

Publication Number Publication Date
WO2018164369A1 true WO2018164369A1 (fr) 2018-09-13

Family

ID=63448214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/000594 Ceased WO2018164369A1 (fr) 2017-03-07 2018-01-12 Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif

Country Status (3)

Country Link
KR (1) KR101924956B1 (fr)
CN (1) CN108834400B (fr)
WO (1) WO2018164369A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432834B1 (ko) * 2019-11-28 2022-08-17 숙명여자대학교산학협력단 식품소재용 무궁화 조성물 및 이의 제조방법
CN111920749A (zh) * 2020-08-31 2020-11-13 滕明军 一种含白芦藜醇的面部精华液及其制备方法
KR102376523B1 (ko) * 2021-06-02 2022-03-17 한남대학교 산학협력단 무궁화나무 수피 추출물을 포함하는 화장료 조성물
JP7681193B2 (ja) * 2021-11-09 2025-05-21 イーエルシー マネージメント エルエルシー 化粧品組成物およびその使用方法
CN115300443B (zh) * 2022-08-02 2023-12-08 银川凤仪堂生物工程有限公司 一种羊胎素提取方法及在化妆品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930022977A (ko) * 1992-05-08 1993-12-18 이덕중 무궁화에서 음료등 기호식품의 첨가물 추출방법
KR0169006B1 (ko) * 1995-10-02 1999-01-15 이분옥 무궁화를 이용한 피부화장료
KR20100059302A (ko) * 2008-11-26 2010-06-04 (주)아모레퍼시픽 목근피 추출물 함유 피부외용제 조성물
KR20110125087A (ko) * 2010-05-12 2011-11-18 (주) 메디플랜 한방추출물을 유효성분으로 하는 소양증 개선용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5129440B2 (ja) 2005-06-14 2013-01-30 共栄化学工業株式会社 植物発酵物及びこれを含む化粧料
JP5957208B2 (ja) * 2011-11-14 2016-07-27 共栄化学工業株式会社 化粧料
CN104906112B (zh) * 2015-05-20 2018-02-23 杨克西 一种促进蛋白质合成的组合物及其制备方法和用途
CN105796445A (zh) * 2016-05-24 2016-07-27 广州丹奇日用化工厂有限公司 一种从慈姑果实中提取慈姑提取物的方法及其应用
CN105997738A (zh) * 2016-07-12 2016-10-12 广州丹奇日用化工厂有限公司 一种含番杏提取物的护肤精华液
CN106176844B (zh) * 2016-08-31 2019-06-14 桂林电子科技大学 一种抗氧化作用强的木槿叶提取物制备方法
CN106236675B (zh) * 2016-09-27 2020-04-28 广东丸美生物技术股份有限公司 一种具有保湿和抗衰老功效的护肤基质及其制备与应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930022977A (ko) * 1992-05-08 1993-12-18 이덕중 무궁화에서 음료등 기호식품의 첨가물 추출방법
KR0169006B1 (ko) * 1995-10-02 1999-01-15 이분옥 무궁화를 이용한 피부화장료
KR20100059302A (ko) * 2008-11-26 2010-06-04 (주)아모레퍼시픽 목근피 추출물 함유 피부외용제 조성물
KR20110125087A (ko) * 2010-05-12 2011-11-18 (주) 메디플랜 한방추출물을 유효성분으로 하는 소양증 개선용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYOO, IN -JA: "Anti-skin aging effect of syriacusins from Hibiscus Syriacus on ultraviolet-irradiated human dermal fibroblast cells", BIOMOLECULES & THERAPEUTICS, 2010, pages 300 - 307, XP053020325, DOI: doi:10.4062/biomolther.2010.18.3.300 *

Also Published As

Publication number Publication date
CN108834400A (zh) 2018-11-16
CN108834400B (zh) 2021-05-04
KR20180102485A (ko) 2018-09-17
KR101924956B1 (ko) 2018-12-04

Similar Documents

Publication Publication Date Title
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
KR102088728B1 (ko) 식물 복합추출물을 유효성분으로 함유하는 피부 탄력 및 주름 개선용 화장료 조성물
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2020071630A1 (fr) Composition pour améliorer la peau comprenant des extraits de produits naturels
KR101908077B1 (ko) 천연 한방 추출물을 유효성분으로 포함하는 미백, 피부 노화 방지 또는 피부 주름 개선용 조성물
KR101849661B1 (ko) 효소 처리된 싸주아리 쑥 추출물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR20240023411A (ko) 보툴리눔 독소 유래 펩타이드 단편, 및 이를 포함하는 피부 주름 개선용 화장료 조성물
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2018097605A2 (fr) Composition contenant un extrait fermenté de complexe de nid de salangane utilisé comme principe actif pour atténuer les rides de la peau, patch permettant d'atténuer les rides de la peau utilisant la composition, et masque de beauté
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2014157910A1 (fr) Composition contenant un extrait de thanaka traité par une enzyme
WO2024063587A1 (fr) Composition d'amélioration de la peau contenant, en tant que principe actif, un extrait de feuille d'eryobotrya japonica induisant une activité d'autophagie
WO2019132217A1 (fr) Composition cosmétique comprenant comme principe actif une solution fermentée du fruit de styphnolobium japonicum ou un extrait liquide de celle-ci et destinée à réduire les rides de la peau, et procédé de préparation associé
KR101877047B1 (ko) 효소 처리된 유칼립투스 추출물을 유효성분으로 함유하는 피부 주름 예방 또는 개선용 조성물
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l'apaisement de la peau ou la cicatrisation des plaies
WO2022050819A1 (fr) Composition anti-inflammatoire pour réduire les rides cutanées et hydrater et activer la régénération de la peau, contenant, en tant que principe actif, un extrait d'huile de krill traitée par une enzyme
KR102139156B1 (ko) 효소처리된 홍삼 및 천마 추출물을 유효성분으로 함유하는 피부주름 예방 또는 개선용 조성물
WO2019225891A1 (fr) Composition contre le vieillissement de la peau contenant de l'irilin b
WO2018151563A1 (fr) Composition pour prévenir le photovieillissement et soulager les rides de la peau, contenant un extrait de cosmos bipinnatus
KR101991936B1 (ko) 효소처리된 천마 추출물을 유효성분으로 함유하는 피부 주름 예방 또는 개선용 조성물
WO2025013954A1 (fr) Composition cosmétique à stabilité améliorée pour améliorer l'élasticité de la peau
WO2017213310A1 (fr) Composition utilisant un extrait de dipterocarpus intricatus pour l'atténuation des rides de la peau
KR101999258B1 (ko) 효소처리된 천마 추출물을 유효성분으로 함유하는 피부상태 개선용 조성물
WO2024158249A1 (fr) Composition pour l'amélioration de la qualité de la peau comprenant un extrait de dillenia indica l. en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18764081

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02.02.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 18764081

Country of ref document: EP

Kind code of ref document: A1